Zai Lab, ZL-1503, ACAAI 2026, Bispecific Antibody, IL-13, IL-31Rα, Atopic Dermatitis, Immunology, Pruritus, Inflammation, Phase 1 Clinical Trial, Biopharmaceutical Research

SHANGHAI and CAMBRIDGE, Mass., October 14, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that initial clinical data...